145 related articles for article (PubMed ID: 35811369)
1. Prognostic outcome of treatment modalities for epidermal growth factor receptor-mutated advanced lung cancer.
Jang SH; Lee DY; Jeong J; Choi WI
Korean J Intern Med; 2022 Jul; 37(4):811-820. PubMed ID: 35811369
[TBL] [Abstract][Full Text] [Related]
2. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcomes in patients with advanced epidermal growth factor receptor-mutated non-small-cell lung cancer in South Western Sydney Local Health District.
Ding PN; Roberts TL; Chua W; Becker TM; Descallar J; Yip PY; Bray V
Intern Med J; 2017 Dec; 47(12):1405-1411. PubMed ID: 28742280
[TBL] [Abstract][Full Text] [Related]
4. Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors as a first-line treatment for postoperative recurrent and EGFR-mutated non-small-cell lung cancer.
Moriya T; Hamaji M; Yoshizawa A; Miyata R; Noguchi M; Tamari S; Chiba N; Miyamoto H; Toyazaki T; Tanaka S; Yamada Y; Yutaka Y; Nakajima D; Ohsumi A; Menju T; Date H
Interact Cardiovasc Thorac Surg; 2022 Feb; 34(3):416-423. PubMed ID: 34652430
[TBL] [Abstract][Full Text] [Related]
5. Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors.
Chang LC; Lim CK; Chang LY; Chen KY; Shih JY; Yu CJ
Eur J Cancer; 2019 Sep; 119():77-86. PubMed ID: 31425965
[TBL] [Abstract][Full Text] [Related]
6. Correlation between the qualification for bevacizumab use and the survival of patients with non-small cell lung cancer harboring the epidermal growth factor receptor mutation: a retrospective analysis.
Hakozaki T; Okuma Y; Hashimoto K; Hosomi Y
J Cancer Res Clin Oncol; 2019 Oct; 145(10):2555-2564. PubMed ID: 31350622
[TBL] [Abstract][Full Text] [Related]
7. Epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation testing in adults with locally advanced or metastatic non-small cell lung cancer: a systematic review and cost-effectiveness analysis.
Westwood M; Joore M; Whiting P; van Asselt T; Ramaekers B; Armstrong N; Misso K; Severens J; Kleijnen J
Health Technol Assess; 2014 May; 18(32):1-166. PubMed ID: 24827857
[TBL] [Abstract][Full Text] [Related]
8. Post-progression survival is highly linked to overall survival in patients with non-small-cell lung cancer harboring sensitive EGFR mutations treated with first-line epidermal growth factor receptor-tyrosine kinase inhibitors.
Imai H; Kaira K; Mori K; Kotake M; Mitani M; Kawashima N; Hisada T; Minato K
Thorac Cancer; 2019 Dec; 10(12):2200-2208. PubMed ID: 31595714
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) monotherapy for advanced EGFR-mutated non-small cell lung cancer: systematic review and meta-analysis.
Lee HJ; Jeong GH; Li H; Kim MS; Kim JS; Park SJ; Han YJ; Lee KH; Kronbichler A; Hong SH; Ghayda RA; Luchini C; Nottegar A; Koyanagi A; Smith L; Jacob L; Dragioti E; Radua J; Cargnin S; Terrazzino S; Thompson T; Yon DK; Lee SW; Yang JM; Wasuwanich P; Shin JI; Gamerith G
Eur Rev Med Pharmacol Sci; 2021 Oct; 25(20):6232-6244. PubMed ID: 34730203
[TBL] [Abstract][Full Text] [Related]
10. Impact of clinical parameters and systemic inflammatory status on epidermal growth factor receptor-mutant non-small cell lung cancer patients readministration with epidermal growth factor receptor tyrosine kinase inhibitors.
Chen YM; Lai CH; Rau KM; Huang CH; Chang HC; Chao TY; Tseng CC; Fang WF; Chung YH; Wang YH; Su MC; Huang KT; Liu SF; Chen HC; Chang YC; Chang YP; Wang CC; Lin MC
BMC Cancer; 2016 Nov; 16(1):868. PubMed ID: 27821111
[TBL] [Abstract][Full Text] [Related]
11. [The concomitant gene alterations impact the therapeutic efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors in advanced non-small cell lung cancer patients with epidermal growth factor receptor sensitive mutation].
Li JM; Hu J; Bai CX; Zhang Y; Xu XB; Wang XD; Ding N
Zhonghua Jie He He Hu Xi Za Zhi; 2018 Oct; 41(10):778-782. PubMed ID: 30347549
[No Abstract] [Full Text] [Related]
12. Key prognostic factors for EGFR-mutated non-adenocarcinoma lung cancer patients in the Japanese Joint Committee of Lung Cancer Registry Database.
Kobayashi K; Soejima K; Fukunaga K; Shintani Y; Sekine I; Shukuya T; Takayama K; Inoue A; Okamoto I; Kiura K; Takahashi K; Yamamoto N; Takiguchi Y; Miyaoka E; Okumura M; Yoshino I;
Lung Cancer; 2020 Aug; 146():236-243. PubMed ID: 32590236
[TBL] [Abstract][Full Text] [Related]
13. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
Soria JC; Ohe Y; Vansteenkiste J; Reungwetwattana T; Chewaskulyong B; Lee KH; Dechaphunkul A; Imamura F; Nogami N; Kurata T; Okamoto I; Zhou C; Cho BC; Cheng Y; Cho EK; Voon PJ; Planchard D; Su WC; Gray JE; Lee SM; Hodge R; Marotti M; Rukazenkov Y; Ramalingam SS;
N Engl J Med; 2018 Jan; 378(2):113-125. PubMed ID: 29151359
[TBL] [Abstract][Full Text] [Related]
14. The association between clinical prognostic factors and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) efficacy in advanced non-small-cell lung cancer patients: a retrospective assessment of 94 cases with EGFR mutations.
Lin JH; Lin D; Xu L; Wang Q; Hu HH; Xu HP; He ZY
Oncotarget; 2017 Jan; 8(2):3412-3421. PubMed ID: 27926500
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the efficacies of first-generation epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in patients with advanced non-small-cell lung cancer harboring EGFR mutations.
Aiko N; Shimokawa T; Miyazaki K; Misumi Y; Agemi Y; Ishii M; Nakamura Y; Yamanaka T; Okamoto H
BMC Cancer; 2018 Oct; 18(1):1012. PubMed ID: 30348116
[TBL] [Abstract][Full Text] [Related]
16. Distinct clinical outcomes of non-small cell lung cancer patients with epidermal growth factor receptor (EGFR) mutations treated with EGFR tyrosine kinase inhibitors: non-responders versus responders.
Hsiao SH; Liu HE; Lee HL; Lin CL; Chen WY; Wu ZH; Lin SE; Chiang LL; Chung CL
PLoS One; 2013; 8(12):e83266. PubMed ID: 24376677
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis.
Qin K; Hou H; Liang Y; Zhang X
BMC Cancer; 2020 Apr; 20(1):328. PubMed ID: 32299384
[TBL] [Abstract][Full Text] [Related]
18. Progression of Central Nervous System Metastases in Advanced Nonsmall Cell Lung Cancer Patients Effectively Treated with First-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor.
Yu M; Zhao Q; Li Y; Zhang S; Xu Y; Gong Y; Zhu J; Ding Z; Wang J; Peng F; Wang Y; Huang M; Ren L; Lu Y; Liu Y
Cancer Biother Radiopharm; 2018 Dec; 33(10):421-426. PubMed ID: 31050549
[TBL] [Abstract][Full Text] [Related]
19. Development and Validation of a Machine Learning Model to Explore Tyrosine Kinase Inhibitor Response in Patients With Stage IV EGFR Variant-Positive Non-Small Cell Lung Cancer.
Song J; Wang L; Ng NN; Zhao M; Shi J; Wu N; Li W; Liu Z; Yeom KW; Tian J
JAMA Netw Open; 2020 Dec; 3(12):e2030442. PubMed ID: 33331920
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of first-line treatment with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) alone or in combination with chemotherapy for advanced non-small cell lung cancer (NSCLC) with low-abundance mutation.
Yan X; Wang H; Li P; Zhang G; Zhang M; Yang J; Zhang X; Zheng X; Ma Z
Lung Cancer; 2019 Feb; 128():6-12. PubMed ID: 30642455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
